Ultragenyx Pharmaceutical (NASDAQ:RARE) EVP Eric Crombez Sells 7,029 Shares

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Eric Crombez sold 7,029 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $160,261.20. Following the completion of the transaction, the executive vice president directly owned 76,301 shares in the company, valued at approximately $1,739,662.80. This represents a 8.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Ultragenyx Pharmaceutical Price Performance

NASDAQ RARE opened at $22.07 on Wednesday. The business’s fifty day moving average is $23.82 and its 200-day moving average is $29.24. The stock has a market capitalization of $2.13 billion, a price-to-earnings ratio of -3.78 and a beta of 0.16. Ultragenyx Pharmaceutical Inc. has a one year low of $18.41 and a one year high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.09). The company had revenue of $207.28 million for the quarter, compared to the consensus estimate of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. Ultragenyx Pharmaceutical’s quarterly revenue was up 25.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.39) EPS. Research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Institutional buying: several large funds have recently increased or initiated stakes (notably Norges Bank and Frazier Life Sciences), which supports a base of long‑term institutional demand and can help stabilize the float. Institutional Inflows
• Neutral Sentiment: Management presentation transcript from TD Cowen’s healthcare conference is available—useful for updating pipeline timelines and modeling but contains no new regulatory or commercial outcomes. TD Cowen Presentation Transcript
• Negative Sentiment: Heavy insider selling by multiple senior executives, including CEO Emil Kakkis (54,404 shares) and several EVPs/C‑suite officers selling material blocks at ~ $22.7–22.8—markets often view clustered executive sales as a negative near‑term sentiment signal. SEC filing for the CEO sale: Insider Sale SEC Filing
• Negative Sentiment: Legal overhang: multiple law firms have circulated investor notices and one class action has been filed alleging misstatements/omissions tied to setrusumab (class period Aug 3, 2023–Dec 26, 2025). Proliferating notices and a filed suit raise potential legal and financial exposure and are likely pressuring the stock. Example filing/notice: Class Action Notice

Analyst Ratings Changes

A number of analysts have issued reports on RARE shares. Bank of America decreased their target price on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating for the company in a research report on Friday, January 2nd. Jefferies Financial Group cut their target price on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a research report on Tuesday, December 30th. Truist Financial dropped their price target on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Wedbush reiterated a “neutral” rating and issued a $25.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, February 17th. Finally, Robert W. Baird dropped their target price on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a research report on Tuesday, December 30th. Sixteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $68.29.

Institutional Trading of Ultragenyx Pharmaceutical

Large investors have recently modified their holdings of the business. Covestor Ltd raised its stake in Ultragenyx Pharmaceutical by 26.0% in the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 369 shares in the last quarter. Huntington National Bank increased its stake in Ultragenyx Pharmaceutical by 56.2% in the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 393 shares during the last quarter. Teacher Retirement System of Texas raised its position in Ultragenyx Pharmaceutical by 1.8% during the second quarter. Teacher Retirement System of Texas now owns 22,773 shares of the biopharmaceutical company’s stock valued at $828,000 after purchasing an additional 404 shares in the last quarter. Xponance Inc. lifted its stake in Ultragenyx Pharmaceutical by 3.1% during the third quarter. Xponance Inc. now owns 13,494 shares of the biopharmaceutical company’s stock worth $406,000 after purchasing an additional 406 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Ultragenyx Pharmaceutical by 2.3% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,988 shares of the biopharmaceutical company’s stock worth $690,000 after purchasing an additional 434 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.